Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 3 of 41.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004210-10 Sponsor Protocol Number: ASSTBS-BLADE-2540-2016 Start Date*: 2017-03-29
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: A PILOT PHASE IV STUDY TO EVALUATE VARIATION IN BONE MINERAL DENSITY, LEAN AND FAT BODY MASS MEASURED BY DUAL-ENERGY X-RAY ABSORPTIOMETRY IN PATIENTS WITH PROSTATE CANCER WITHOUT BONE METASTASIS T...
    Medical condition: prostate cancer prostate cancer without bone metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001786-18 Sponsor Protocol Number: CZOL446GDE08 Start Date*: 2005-03-22
    Sponsor Name:EAU EUROPEAN ASSOCIATION OF UROLOGY
    Full Title: Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EA...
    Medical condition: Prevention of bone metastasis in high risk prostate cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007666-38 Sponsor Protocol Number: BR1-127 Start Date*: 2008-11-28
    Sponsor Name:Bracco Imaging SPA
    Full Title: A phase III study to compare SonoVue guided prostate biopsy with systematic biopsy in the detection of prostate malignant lesions in patients with suspected prostate cancer
    Medical condition: Patients with suspected prostate cancer (For the optimization part: patients with a diagnosis of prostate cancer).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) NL (Completed) GB (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000101-69 Sponsor Protocol Number: EGD-EC-005 Start Date*: 2013-07-04
    Sponsor Name:Astellas Pharma Europe Ltd. (APEL)
    Full Title: An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer.
    Medical condition: Patients with metastatic prostate cancer whom androgen deprivation therapy (ADT) is indicated
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001650-77 Sponsor Protocol Number: FE200486 CS18 Start Date*: 2007-05-14
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring ...
    Medical condition: Patients with prostate cancer requiring androgen ablation therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-021287-16 Sponsor Protocol Number: 9785-CL-0321 Start Date*: 2010-11-29
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer
    Medical condition: Hormone-naïve prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002345-29 Sponsor Protocol Number: T83/2017 Start Date*: 2018-08-10
    Sponsor Name:Turku University Hospital
    Full Title: The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in prostate cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005479-42 Sponsor Protocol Number: A301226 Start Date*: 2014-06-04
    Sponsor Name:Erasmus MC, Dept. Urology
    Full Title: Pilot study: Toxicity of oestradiol for adjuvant endocrine therapy in locally confined prostate cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002880-98 Sponsor Protocol Number: CRO-04-62 / GP/C/03/PRO Start Date*: 2005-11-25
    Sponsor Name:GP-Pharm s.a.
    Full Title: Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.0 10007113 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) CZ (Completed) HU (Completed) IT (Completed) DE (Completed) SK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022064-12 Sponsor Protocol Number: EFC11784 Start Date*: 2011-03-23
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients wit...
    Medical condition: metastatic Castration Resistant Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) FI (Completed) DK (Completed) PT (Completed) IT (Completed) DE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019632-12 Sponsor Protocol Number: A-94-5214-178 Start Date*: 2010-10-19
    Sponsor Name:IPSEN Pharma GmbH
    Full Title: A phase II, multicentre, open, prospective, randomised, parallel-group, pharmacodynamic equivalence study on intramuscular versus subcutaneous applications of Triptorelin pamoate (Pamorelin® LA 11....
    Medical condition: advanced prostate cancer (locally advanced or metastatic)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003165-15 Sponsor Protocol Number: FACBC-STAGING-2014 Start Date*: 2014-12-02
    Sponsor Name:AOU di Bologna Policlinico S.Orsola-Malpighi
    Full Title: 18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCER
    Medical condition: Patients affected by moderate to high risk primary prostate cancer who are scheduled for surgery with a planned, elective lymph node dissection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10036946 Prostatic cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001034-18 Sponsor Protocol Number: PETMR-Staging-PCa1 Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study to evaluate a novel approach for staging prostate cancer patients by using a fully integrated hybrid PET/MRI
    Medical condition: Patient diagnosed with prostatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007028-25 Sponsor Protocol Number: ON/2008/2781 Start Date*: 2010-08-17
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex)
    Medical condition: Enrolled patients will be those with a diagnosis of prostate cancer who require radiotherapy to the prostate, with medical castration by means of Luteneising Hormone Releasing Hormone analogue (LRH...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006827-29 Sponsor Protocol Number: FE200486CS34 Start Date*: 2009-04-27
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: Ensayo clínico fase IIIb, no aleatorizado, abierto, multicéntrico, de seguimiento de la seguridad de dosis mensuales de degarelix en pacientes con cáncer de próstata. A Phase 3b, Non-randomized, O...
    Medical condition: Cáncer de próstata
    Disease: Version SOC Term Classification Code Term Level
    9 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) FI (Completed) SE (Completed) PT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012786-58 Sponsor Protocol Number: 8-79-52014-168 Start Date*: 2009-12-07
    Sponsor Name:Ipsen Pharma SAS
    Full Title: PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (P...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed) LV (Completed) FR (Completed) NL (Completed) LT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010079-25 Sponsor Protocol Number: LPC-002 Start Date*: 2009-05-11
    Sponsor Name:LIDDS AB
    Full Title: An open, single and multiple dose, efficacy and safety Proof of Principle study of Liproca® Depot, a controlled release formulation of 2-hydroxyflutamide, injected into the prostate in patients wi...
    Medical condition: prostate cancer (T1-T2), Gleason ≤ 3+4 at the time of diagnose in prostate biopsy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-004782-40 Sponsor Protocol Number: PEM-PRO Start Date*: 2020-09-24
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: An open label, single-arm, phase 2 study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in high-risk prostate cancer patients
    Medical condition: High-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004355-30 Sponsor Protocol Number: 20070611 Start Date*: 2009-01-05
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer
    Medical condition: Previously Treated Castrate Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) FR (Completed) NL (Completed) FI (Completed) SE (Completed) BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002511-99 Sponsor Protocol Number: IOV-PR-CH-PET-1-2013 Start Date*: 2013-11-25
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO
    Full Title: Role of PET/ CT with 18F-fluorocholine in the staging of patients with intermediate/high risk prostate cancer. Phase III, randomized, open-label clinical trial
    Medical condition: Histologically proven prostate cancer with Gleason score =7 and PSA>=10ng/ml or Gleason score >=8 and any PSA level or cT2-T3 and any PSA level or any Gleason score and PSA>=20ng/ml and indication ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 22:40:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA